Literature DB >> 15936837

MPTP treatment in mice does not transmit and cause Parkinsonian neurotoxicity in non-treated cagemates through close contact.

Yuen-Sum Lau1, Lesya Novikova, Christina Roels.   

Abstract

1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is currently a leading neurotoxic agent used for producing Parkinsonism in laboratory animals. The MPTP neurotoxicity in humans is irreversible and the consequential clinical and neurochemical features closely resemble those of the idiopathic Parkinson's disease. Therefore, handling of MPTP in laboratory may pose neurotoxic risk among researchers and animal caretakers. While it is well recognized that systemic administration of MPTP will cause Parkinsonian-like symptoms in humans and animals, it is not known whether similar neurological toxicity is transmittable and would develop in normal subjects housed closely with the MPTP-treated animals. In the present study, we treated mice daily with MPTP hydrochloride (30mg/kg, s.c.) for 5 consecutive days. In the same cage, a non-treated mouse (cagemate) was kept allowing for close physical interaction, free contact with the excreta, and sharing of food and water. Seventy-two hours after the treatment, the MPTP-treated mice and MPTP-exposed cagemates were analyzed for dopaminergic neurotoxicity comparing with the MPTP non-exposed control animals. We detected a significant number of TUNEL-positive cells, loss of tyrosine hydroxylase immunoreactivity in the substantia nigra, and depletion of dopamine in the striatum of MPTP-treated mice. However, these neurotoxic indices were not detected in the MPTP-exposed cagemates or MPTP non-exposed controls. Following each MPTP injection, approximately 42% of the chemical was excreted within 3h through the urine largely in the form of MPTP N-oxide, which is not expected to cross the blood-brain barrier and to cause dopaminergic toxicity in the brain when administered peripherally. These observations suggest that MPTP injections in mice do not transmit and cause Parkinsonian-like dopaminergic neurotoxicity in the neighboring normal cagemates through direct physical contact and exposure from the contaminated cage, food, water, and excreta.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15936837     DOI: 10.1016/j.neures.2005.04.010

Source DB:  PubMed          Journal:  Neurosci Res        ISSN: 0168-0102            Impact factor:   3.304


  13 in total

1.  Increased renal dopamine and acute renal adaptation to a high-phosphate diet.

Authors:  Edward J Weinman; Rajatsubhra Biswas; Deborah Steplock; Peili Wang; Yuen-Sum Lau; Gary V Desir; Shirish Shenolikar
Journal:  Am J Physiol Renal Physiol       Date:  2011-02-16

2.  Neuroprotective effects and mechanisms of exercise in a chronic mouse model of Parkinson's disease with moderate neurodegeneration.

Authors:  Yuen-Sum Lau; Gaurav Patki; Kaberi Das-Panja; Wei-Dong Le; S Omar Ahmad
Journal:  Eur J Neurosci       Date:  2011-03-07       Impact factor: 3.386

3.  Escin, a novel triterpene, mitigates chronic MPTP/p-induced dopaminergic toxicity by attenuating mitochondrial dysfunction, oxidative stress, and apoptosis.

Authors:  Govindasamy Pushpavathi Selvakumar; Thamilarasan Manivasagam; Karamkolly R Rekha; Richard L Jayaraj; Namasivayam Elangovan
Journal:  J Mol Neurosci       Date:  2014-05-02       Impact factor: 3.444

4.  Melatonin protects against neurobehavioral and mitochondrial deficits in a chronic mouse model of Parkinson's disease.

Authors:  Gaurav Patki; Yuen-Sum Lau
Journal:  Pharmacol Biochem Behav       Date:  2011-07-01       Impact factor: 3.533

5.  Squamosamide derivative FLZ protected tyrosine hydroxylase function in a chronic MPTP/probenecid mouse model of Parkinson's disease.

Authors:  Xiu-Qi Bao; Liang-Yu Wu; Xiao-Liang Wang; Hua Sun; Dan Zhang
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2015-02-13       Impact factor: 3.000

6.  Gene-environment interaction models to unmask susceptibility mechanisms in Parkinson's disease.

Authors:  Vivian P Chou; Novie Ko; Theodore R Holman; Amy B Manning-Boğ
Journal:  J Vis Exp       Date:  2014-01-07       Impact factor: 1.355

7.  Mitochondrial dysfunction in the striatum of aged chronic mouse model of Parkinson's disease.

Authors:  Gaurav Patki; Yi Che; Yuen-Sum Lau
Journal:  Front Aging Neurosci       Date:  2009-12-11       Impact factor: 5.750

8.  Upregulation of renal D5 dopamine receptor ameliorates the hypertension in D3 dopamine receptor-deficient mice.

Authors:  Xiaoyan Wang; Crisanto S Escano; Laureano Asico; John E Jones; Alan Barte; Yuen-Sum Lau; Pedro A Jose; Ines Armando
Journal:  Hypertension       Date:  2013-06-10       Impact factor: 10.190

9.  Endurance exercise promotes cardiorespiratory rehabilitation without neurorestoration in the chronic mouse model of parkinsonism with severe neurodegeneration.

Authors:  M Al-Jarrah; K Pothakos; L Novikova; I V Smirnova; M J Kurz; L Stehno-Bittel; Y-S Lau
Journal:  Neuroscience       Date:  2007-08-11       Impact factor: 3.590

10.  Renal dopaminergic defect in C57Bl/6J mice.

Authors:  Crisanto S Escano; Ines Armando; Xiaoyan Wang; Laureano D Asico; Annabelle Pascua; Yu Yang; Zheng Wang; Yuen-Sum Lau; Pedro A Jose
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2009-09-02       Impact factor: 3.619

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.